Home
Broegelmann Research Laboratory

Silke Appel Group

Single cell network profiling of distinct immune cells allows analyzing pathway specific activity of patient samples at the single cell level. This will enable us to stratify different categories of patients and develop personalized therapies. The overall aim of our research is to further unravel the mechanisms by which dendritic cells modulate T cell responses, both in autoimmunity as well as tumor immunity. Our results will lead to a better understanding of the cellular mechanisms involved in antigen presentation, T cell stimulation and tolerance induction, thereby revealing new tools for diagnosis and targets for therapy of patients with cancer, autoimmune and infectious diseases as well as patients undergoing stem cell transplantation. Thus, it will lead to an increased survival and better quality of life for patients.

Main content

Projects and current members within the group

 

Dorentina Osmani, PhD fellow

Novel COVID-19 therapy based on natural products with anti-SARS-CoV-2 activity. By the end of 2022, COVID-19 has caused 6,65 million deaths since its outbreak in late December 2019. Treatment for patients infected with SARS-CoV-2 includes antiviral therapy.  Dorentina is working towards testing natural products isolated from terrestrial plants for SARS-CoV-2 antiviral effects, especially the polyphenolic secondary metabolites: Flavonoids. Currently, work on cell-based assays investigating the naturalizing effects the natural products have on the entry of the virus via the host receptors ACE2 and TMPRSS2 are being performed. In the future,  Dorentina wishes to investigate the effects natural products have on the replication cycle of the virus in host cells.